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Abstract
Herein, we show that PTX-B and its non-toxic mutant PT9K/129G inhibit transcription and secretion of TGF-b elicited by
HIV-1 Tat in NK cells. Moreover, Tat strongly activates the cJun component of the multimolecular complex AP-1, while
TGF-b triggers cFos and cJun. Treatment of NK cells In turn,with PTX-B or PT9K/129G inhibits Tat and TGF-b-induced
activation of AP-1. TGF-b enhances starvation-induced NK cell apoptosis, reduces the transcription of the antiapoptotic
protein Bcl-2 and inhibits Akt phosphorylation induced by oligomerization of the triggering NK cell receptor NKG2D. All
these TGF-b-mediated effects are prevented by PTX-B or PT9K/129G, through a PI-3K-dependent mechanism. Finally,
PTX-B and PT9K/129G upregulate Bcl-xL, the isoform of Bcl-x that protects cells from starvation-induced apoptosis. Of
note, in NK cells from patients with HIV-1 infection, mRNA expression of Bcl-2 and Bcl-xL was consistently lower than that
of healthy donors; interestingly, TGF-b and Tat were detected in the sera of these patients. These data suggest that
Tat-induced TGF-b production and the consequent NK cell failure, possibly occurring during early HIV-1 infection, may
be regulated by PTX-B and PT9K/129G.
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Introduction
HIV-1 infection has been shown to induce production
of several cytokines which, in turn, modulate the levels
of HIV-1 expression in infected cells: this double-
edged mechanism is supposed to play an important
role in the pathogenesis of AIDS (Poli and Fauci
1993). HIV-1 products, among which endogenous
Tat, induce the transcription of cytokines with
immunosuppressive effects, including transforming
growth factor (TGF)-b: regulation of TGF-b trans-
cription by Tat has been claimed to contribute to
immunosuppression in AIDS (Reinhold et al. 1999).
We and others have reported on the possible
immunosuppressive effects of extracellular Tat once
taken up by bystander cells (Rubartelli et al. 1998;
Z o c c h ie ta l .1 9 9 8 ;P o g g ie ta l .2 0 0 2 ) .T h u s ,
a possibility exists that also exogenous Tat can induce
TGF-b transcription in immunocompetent cells.
The transactivating effect of HIV-1 Tat is mediated
by the multimolecular complex AP-1; interestingly,
the same pathway is activated by TGF-b, which acts
mainly upregulating the Jun family of AP-1 transcrip-
tion factors (Gibellini et al. 1997; Cohen et al. 1999).
In addition, TGF-b has been reported to induce
apoptosis of different cell types through AP-1-
dependent activation of SHIP which, in turn,
determines the dephosphorylation of Akt, a phospho-
inositol-3 kinase (PI-3K)-dependent enzyme that
induces the transcription of the antiapoptotic proteins
Bcl-2 and Bcl-x (Yamamura et al. 2000; Valderrama-
Carvajal et al. 2002). The dephosphorylated form of
Akt is inactive leading to down-regulation of Bcl-2
and Bcl-x transcription (Chao et al. 1998; Pugaz-
henthi et al. 2000). Suppression of TGF-b-induced
apoptosis can be reached by upregulating the PI-
3K/Akt pathway and pAkt that downregulates AP-1
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with a mechanism controlling both Tat and TGF-b-
mediated effects.
HIV-1 Tat induces TGF-b production, inhibited by PTX-
B through the block of AP-1
We found that synthetic Tat induces very early
transcription and secretion of TGF-b in NK cells;
interestingly, both transcription and secretion of
TGF-b are inhibited by a short exposure (10min) of
NK cells to the PTX-B oligomer or to the non-toxic
mutant of PTX, PT9K/129G (both at 1nM), which
can be safely administered in vivo (Del Giudice et al.
1999). As reported (Gibellini et al. 1997), Tat induces
the activation of AP-1, preferentially involving cJun in
NK cells; of note, this activation is inhibited by either
PTX-B or by PT9K/129G. TGF-b also induces AP-1
(Yamamura et al., 2000), thus possibly creating a
positive loop on its synthesis and secretion; we found
that exposure of NK cells to 10ng/ml of TGF-b leads
to a strong activation of cFos and, to a lesser extent, of
cJun; again, pre-treatment of NK cells with either
PTX-B or PT9K/129G (1nM) abolished cFos and
strongly inhibited cJun activation. The blocking effect
of PTX-B or PT-9K/129G on Tat or TGF-b-induced
cJun activation was abolished by LY294002,
suggesting that both PTX-B and its mutant act mainly
through PI-3K activation (Figure 1 shows a proposed
model of these interactions).
PTX-B and PT9K/129G maintain Akt phosphorylation
and Bcl-xL/Bcl-2 trancription and inhibit TGF-b-
mediated NK cell apoptosis
It is known that TGF-b is a mediator of apoptosis in
different cell types (Yamamura et al. 2000): we found
that it is able to accelerate starvation-induced
apoptosis in NK cells. Indeed, about 8% of NK cells
were apoptotic, evaluated as PI
þ cells that identiﬁes
apoptotic cells (DNA content ,2n), after 48h of in
the absence of growth factors (IL2), being approxi-
mately 35% in the presence of 10ng/ml of TGF-b,
while ,10% of apoptotic cells were detected after
pretreatment with PTX-B or with PT9K/129G,
before exposure to TGF-b. Of note, NK cell apoptosis
was also detected after 48h of NK cells cultured in the
presence of supernatants from autologous NK cells
treated for 24h with Tat, containing 20ng/ml of
TGF-b: this apoptosis was blocked by adding
neutralizing anti-TGF-b mAb (5mg/ml), further
supporting a Tat-induced TGF-b-mediated autocrine
pathway. We investigated the molecular mechanism
whereby PTX-B antagonizes TGF-b: this cytokine is
known to induce dephosphorylation of Akt, thus
impairing the protection from apoptosis (Valderrama-
Carvajal et al. 2002). Interestingly, PTX is an
activator of PI-3K, which in turn leads to phosphoryl-
ation and activation of Akt (Pugazhenthi et al. 2000).
In keeping with this, we found that the percentage of
pAkt vs total Akt increased from 5 to 25% at 8min,
Figure 1. Proposed mechanism of action of Tat and TGF-b and role of PTX-B and PT-9K/129G. Tat induces ERK1/2 which activate AP-1,
responsible for TGF-b production. TGF-b itself can activate ERK1/2 and AP-1 through SMAD3/4: both these steps are inhibited by ERK1/2
inhibitors. A further effect of TGF-b?is the dephosphorylation of Akt, elicited through a double mechanism: activation of SHIP and/or of
calcineurin. The downregulation of Akt leads to a decrease in the synthesis of anti-apoptotic proteins such as Bcl-2 and Bcl-x. On the contrary,
PTX-B or its non-toxic mutant PT9K/129G activates PI-3K maintaining the phosphorylated form of Akt and the synthesis of antiapoptotic
proteins: this pathway is blocked by PI-3K inhibitors, such as LY294002.
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PT9K/129G: this effect was blocked in the presence of
the PI-3K blocker LY294002, supporting the hypoth-
esis that PTX-B acts through the activation of PI-3K
(Figure 1). Phosphorylated Akt is known to induce
transcription of the antiapoptotic proteins Bcl-2
a n dB c l - x ;i np a r t i c u l a r ,B c l - x L is involved in
the protection from starvation-induced apoptosis
(Yamamura et al. 2000). TGF-b-induced apoptosis
is the consequence of Akt dephosphorylation and this
effect can be counteracted by upregulating the PI-3K-
dependent Akt pathway (Yamamura et al. 2000;
Valderrama-Carvajal et al. 2002). Accordingly, in NK
cells exposed to TGF-b a reduction by 80% of Bcl-2
transcript was observed, while Bcl-xL mRNA was
undetectable. Treatment with PTX-B or with
PT9K/129G, not only prevented the inhibitory effect
of TGF-b on Bcl-2, but also induced Bcl-xL
transcription, even in the presence of TGF-b.
Bcl-2 and Bcl-xL transcription is down-regulated in NK
cells from HIV-1 patients showing TGF-b and Tat in their
Serum
To verify the in vivo relevance of our ﬁndings, we
studied 20 HIV-1 infected patients at stage A of the
disease. We evaluated the mRNA for Bcl-2, Bcl-xL and
Bcl-xS in puriﬁed NK cells and PBMC obtained from
these patients, compared to NK cells and PBMC from
healthy donors, matched for sex and age. As shown in
table I, the levelof Bcl-xLand Bcl-2 mRNA transcripts
was consistently lower in puriﬁed NK cells (Table I) or
in unfractionated PBMC (not shown) of HIV-1
infected patients than in healthy donors. TGF-b was
present in the serum of all HIV-1 patients: in
particular, in 13 out of 20 patients serum levels of
TGF-b ranged between 50 and 100ng/ml, while in
healthy donors tested TGF-b was always ,10ng/ml
(n ¼ 15, Table I). In six patients, Tat was detectable in
the serum at 10–50nM concentration, and viremia
was found (HIV-1 mRNA ranging between 1000 and
24,000 copies/ml) in eleven patients. Interestingly,
regression analysis showed that RNA copy number is
signiﬁcantly associated with TGF-b (r ¼ 0.70) and
Tat (r ¼ 0.77) serum levels. Moreover, in these
patients the percentage of CD3
2CD16
þ (NK) cells
was consistently lower (7 ^ 3%) than in patients with
low or undetectable TGF-b or Tat (14 ^ 4%) or in
healthy donors (15 ^ 3%) (Table I).
Conclusions
We have demonstrated that HIV-1 Tat induces both
transcription and secretion of TGF-b which, in turn,
Table I. Increase of TGF-b and detection of HIV-1 Tat in the serum of patients with high HIV-1 and low Bcl-2/Bcl-xL mRNA
Pt. CD4/CD8 ratio*
CD3
2CD16
+ cells
(%)* Bcl-x L/GAPDH %
† Bcl-2/GAPDH %
†
HIV-1 RNA
(copies/ml
21)‡
TGF-b
(ng/ml)
{
Tat
(nM)
§
1 0.2 4 1 (29) 10 (30) 24,000 95 40
2 0.5 5 2 (42) 12 (22) 17000 90 50
3 0.4 6 5 (36) 9 (38) 9000 100 50
4 1.0 4 4 (41) 8 (44) 8100 85 10
5 1.0 3 6 (40) 11 (43) 6800 80 20
6 0.5 7 2 (36) 12 (26) 6000 100 40
7 0.1 10 3 (45) 10 (33) 5000 105 30
8 0.8 8 2 (53) 9 (23) 2700 100 50
9 0.9 5 3 (51) 8 (31) 900 95 40
10 1.0 12 2 (48) 9 (28) 900 50 20
11 1.0 11 4 (36) 10 (39) 900 35 10
12 1.2 10 3 (40) 8 (30) 800 55 10
13 1.0 12 2 (50) 12 (40) ,80 100 20
14 1.3 18 3 (38) 11 (37) ,80 28 n.d.
15 1.7 14 2 (37) 6 (29) ,80 20 n.d.
16 2.9 18 5 (37) 8 (35) ,80 15 n.d.
17 1.2 12 4 (50) 9 (40) ,80 80 10
18 1.1 15 5 (44) 7 (34) ,80 20 n.d
19 1.5 13 4 (36) 12 (46) ,80 15 n.d.
20 1.3 16 6 (42) 10 (43) ,80 30 n.d.
*CD4
þ or CD8
þ and CD3
2CD16
þ cells were evaluated by immunoﬂuorescence with the speciﬁc mAbs and FACS analysis. The percentage
of CD3
2CD16
þ cells and CD4/CD8 ratio in the peripheral blood of 15 healthy donors tested for comparison was 15 ^ 3 and 1.7 ^ 0.4,
respectively.
†Densitometric analysis of Bcl-2 and Bcl-xL mRNA evaluated by PCR in puriﬁed NK cells from 20 HIV-1-infected patients or 10
healthy donors (in parenthesis) expressed as Bcl-2 or Bcl-xL percentage of GAPDH analysed in the same sample.
‡HIV-1 RNA was
quantitated using the commercial branched DNA (bDNA ultrasensitive Assay, Chiron) with a lower limit of detection of 50 RNA copies/ml.
{TGF-b has been measured in the sera of HIV-1 infected patients by an ELISA commercial kit. Results expressed as ng/ml referred to the
standard. TGF-b in the sera of 15 healthy donors tested for comparison was 8 ^ 2ng/ml.
§Tat was measured using a polyclonal rabbit anti-Tat
antiserum (10mg/ml) as capture antibody and a biotinilated rabbit anti-Tat antiserum (1mg/ml) as detection antibody, followed by Av-HRP
and by the speciﬁc substrate. Results expressed as nM referred to synthetic Tat (Tecnogen) used as standard. n.d.: not detectable. Tat
measured in the sera of 15 healthy donors tested for comparison was ,1nM.
HIV-1 Tat triggers TGF-b production 371accelerates starvation-induced NK cell apoptosis,
inhibits Akt phosphorylation and down-regulates
Bcl-xL and Bcl-2 transcription. These mechanisms,
if operating in vivo, would lead to either functional
impairment or even elimination of cells involved in
early anti-viral response. Of note, PTX-B and its non-
toxic mutant PT9K/129G, are able to counteract all
these biochemical events in NK cells, through a PI-
3K/Akt-dependent mechanism (Figure 1). The
pathological relevance of our data is supported by
the ﬁnding that in NK cells from patients with early
HIV-1 infection, Bcl-xL and, to a lesser extent, Bcl-2
mRNA expression was consistently lower than that of
healthy donors (table I); moreover, TGF-b, and in
two thirds of the cases Tat, was detected in the sera of
these patients, at concentrations which are biologically
active in vitro (table I). We cannot exclude that, in
these patients, TGF-b is produced by other cells than
NK cells, including antigen presenting cells, endo-
thelial cells or stromal cells in the lymph nodes, where
similar Tat-mediated effets might be operative as well,
thus possibly amplifying the immunosuppressive
effect. Nevertheless, administration of PT9K/129G,
which is already approved for human use as a
component of a vaccine against B. pertussis infection
(Roberts et al. 1995; Del Giudice et al. 1999), as a
component of a Tat-based vaccine in HIV-1-infected
patients might be of interest, not only as an adjuvant
but also as a component potentially able to interfere
with HIV-1 replication (Alfano et al. 2000; 2001),
with unwanted Tat and with cytokine-mediated
immunosuppressive action [2–4], allowing the ﬁrst
anti-viral defense to be maintained.
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